Cargando…
Epigallocatechin-3-gallate inhibits the growth and increases the apoptosis of human thyroid carcinoma cells through suppression of EGFR/RAS/RAF/MEK/ERK signaling pathway
BACKGROUND: Thyroid cancer is the most common type of endocrine malignancy and the incidence rate is rapidly increasing worldwide. Epigallocatechin-3-gallate (EGCG) could suppress cancer growth and induce apoptosis in many types of cancer cells. However, the mechanism of action of EGCG on the growth...
Autores principales: | Wu, Dongdong, Liu, Zhengguo, Li, Jianmei, Zhang, Qianqian, Zhong, Peiyu, Teng, Tieshan, Chen, Mingliang, Xie, Zhongwen, Ji, Ailing, Li, Yanzhang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394055/ https://www.ncbi.nlm.nih.gov/pubmed/30858760 http://dx.doi.org/10.1186/s12935-019-0762-9 |
Ejemplares similares
-
Peptide V3 Inhibits the Growth of Human Hepatocellular Carcinoma by Inhibiting the Ras/Raf/MEK/ERK Signaling Pathway
por: Wu, Dongdong, et al.
Publicado: (2019) -
Epigallocatechin-3-Gallate Alleviates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease via Inhibition of Apoptosis and Promotion of Autophagy through the ROS/MAPK Signaling Pathway
por: Wu, Dongdong, et al.
Publicado: (2021) -
Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer
por: Gonzalez-Hormazabal, Patricio, et al.
Publicado: (2018) -
Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
por: Degirmenci, Ufuk, et al.
Publicado: (2020) -
Reusability and composability in process description maps: RAS–RAF–MEK–ERK signalling
por: Mazein, Alexander, et al.
Publicado: (2021)